EL7.AI
StocksMediumUpdated•Originally published 23 March 2026•Updated 25 March 2026•
1 min read

Apogee Therapeutics Upsizes Public Offering to $350 Million at $70 Per Share

Key Facts

1Apogee Therapeutics announced the commencement of an underwritten public offering of $300 million of its common stock.
2Underwriters are expected to be granted a 30-day option to purchase up to an additional $45 million of common stock.
3The company is a clinical-stage biotech focused on biologics for inflammatory and immunology (I&I) markets.

Apogee Therapeutics, Inc. (Nasdaq: APGE) has priced its upsized public offering of common stock at $70.00 per share, raising the total expected gross proceeds to $350 million from the previously announced $300 million. The offering consists of 5,000,000 shares of common stock, with underwriters granted a 30-day option to purchase an additional 750,000 shares. This clinical-stage biotechnology firm intends to use the capital to advance its pipeline of biologics for inflammatory and immunology (I&I) markets and for general corporate purposes. The offering is scheduled to close on March 26, 2026, subject to customary closing conditions. While the increased capital provides a stronger financial cushion for research and development, the market is assessing the potential for equity dilution. Investors are closely watching APGE's performance on the Nasdaq as the market absorbs the increased supply of shares.